GlassScriptPhysician profile
Joseph Ghazal
NPI 1275558330
$6,801.68
in general payments reported to CMS, 2019-2025
19 companies · $5,410 in 2025
The $5,410 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $66.38 · 2021: $272 · 2022: $78.68 · 2023: $377 · 2024: $461 · 2025: $5,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,995 · Food and Beverage: $1,234 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,995.00 |
| Food and Beverage | $1,233.50 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $5,199.94 | 2021-2025 | Venclose Maven Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $281.50 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $199.55 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.68 | 2023-2025 | Jardiance |
| Abbott Laboratories | $182.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $157.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $98.93 | 2024-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $86.94 | 2021-2024 | Farxiga |
| Novo Nordisk INC | $74.94 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $73.68 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $56.78 | 2023-2024 | Varithena Administration Pack, Watchman |
| Lilly USA, LLC | $32.70 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $28.04 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.54 | 2020 | |
| Medtronic Vascular, INC. | $25.24 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $24.84 | 2024 | |
| Heartflow, INC. | $22.21 | 2024 | |
| Cvrx, INC. | $20.49 | 2024 | Barostim Neo System |
| Medline Industries LP | $20.06 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ghazal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.